文献速递临床试验与 GCP真实世界研究与卫生经济

Seattle-PAP用于早产儿呼吸支持疗效评估:随机对照试验方案

Evaluating the efficacy of Seattle-PAP for the respiratory support of premature neonates: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-01-18

本研究为多中心、非盲法随机对照试验,计划纳入230例胎龄220/7至296/7周的早产儿,随机分配接受Seattle-PAP或FP-CPAP无创呼吸支持。主要结局为需插管和机械通气的呼吸衰竭,次要结局包括短期和长期呼吸系统疾病发病率及成本效益。该试验旨在评估Seattle-PAP在真实临床实践中是否比FP-CPAP更有效且更具成本效益。

要点

  • 试验比较Seattle-PAP与FP-CPAP两种 bubble nCPAP 方式在早产儿中的疗效。
  • 主要结局是需插管和机械通气的呼吸衰竭。
  • 计划纳入230例胎龄220/7至296/7周的早产儿,多中心非盲法随机对照设计。

核心结论

  • 该试验将评估Seattle-PAP是否比FP-CPAP在真实临床实践中更有效且更具成本效益。

研究设计与样本

  • 多中心、非盲法随机对照试验,计划纳入230例胎龄220/7至296/7周的早产儿。
  • 婴儿随机分配接受Seattle-PAP或FP-CPAP。

关键数值与推荐

  • 主要结局为需插管和机械通气的呼吸衰竭。
  • 次要结局包括短期和长期呼吸系统疾病发病率及成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At birth, the majority of neonates born at <30 weeks of gestation require respiratory support to facilitate transition and ensure adequate gas exchange. Although the optimal approach to the initial respiratory management is uncertain, the American Academy of Pediatrics endorses noninvasive respiratory support with nasal continuous positive airway pressure (nCPAP) for premature neonates with respiratory insufficiency. Despite evidence for its use, nCPAP failure, requiring intubation and mechanical ventilation, is common. Recently, investigators have described a novel method to deliver bubble nCPAP, termed Seattle-PAP. While preclinical and pilot studies are encouraging regarding the potential value of Seattle-PAP, a large trial is needed to compare Seattle-PAP directly with the current standard of care for bubble nCPAP (Fisher & Paykel CPAP or FP-CPAP). METHODS/DESIGN: We designed a multicenter, non-blinded, randomized controlled trial that will enroll 230 premature infants (220/7 to 296/7 weeks of gestation). Infants will be randomized to receive Seattle-PAP or FP-CPAP. The primary outcome is respiratory failure requiring intubation and mechanical ventilation. Secondary outcomes include measures of short- and long-term respiratory morbidity and cost-effectiveness. DISCUSSION: This trial will assess whether Seattle-PAP is more efficacious and cost-effective than FP-CPAP in real-world practice among premature neonates. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03085329 . Registered on 21 March 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Backes CH, Notestine JL, Lamp JM, et al. Evaluating the efficacy of Seattle-PAP for the respiratory support of premature neonates: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30658678. doi:10.1186/s13063-018-3166-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。